Independent Safety Committee unanimously agrees that the Phase I/II trial is safe, well tolerated, and fit for expanded accessStudy achieving primary endpoints of safety, tolerability, and efficacy by resolving/curing bacterial infections in patients with diabetic foot ulcersRECCE® 327 dosed daily or every second day for 14 days is considered to be safe and well-toleratedAdditional clinical sites to be launched in Australia, and additional clinical trials will be launched internationally in diab
Breakthroughs in biotech bring us closer to better health proactiveinvestors.com.au - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com.au Daily Mail and Mail on Sunday newspapers.
Memorandum of Understanding (MoU) with leading Indonesian biomedical company PT Etana BiotechnologiesMoU aims to facilitate late-stage clinical trials in Indonesia, supporting the Indonesian Government’s access to novel infectious disease medicinesOpportunity to access 10 ASEAN member states1 covering a population of 670 million inhabitantsPatient populations readily available focused on significant unmet medical needs particular to the regionSignificant bilateral initiative supported by the Aus
Recce Pharmaceuticals in MoU with Indonesian biotech to accelerate clinical development of anti-infectives proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.
Recce the arch enemy of foot infections couriermail.com.au - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from couriermail.com.au Daily Mail and Mail on Sunday newspapers.